INITIAL RESULTS FROM THE SAPHIRE STUDY: A PHASE II TRIAL WITH THE NOVEL ORAL HISTONE DEACETYLASE (HDAC) INHIBITOR RESMINOSTAT IN RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA PATIENTS

被引：0
|
作者：
Walewski, J. [1 ]
Paszkiewicz-Kozik, E. [1 ]
Borsaru, G. [2 ]
Moicean, A. [3 ]
Warszewska, A. [1 ]
Strobel, K. [4 ]
Biggi, A. [5 ]
Hauns, B. [6 ]
Mais, A. [6 ]
Henning, S. [6 ]
Hentsch, B. [6 ]
机构：
[1] Marie Curie Mem Canc Ctr, Warsaw, Poland
[2] Clin Hosp Coltea, Bucharest, Romania
[3] Fundeni Clin Inst, Bucharest, Romania
[4] Luzerner Kantonspital, Luzern, Switzerland
[5] S Croce Hosp, Cuneo, Italy
[6] 4SC AG, Martinsried, Germany
来源：
HAEMATOLOGICA | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
C091
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [1] Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor
    Walewski, Jan
    Paszkiewicz-Kozik, Ewa
    Borsaru, Gabriela
    Moicean, Andreea
    Warszewska, Agnieszka
    Strobel, Klaus
    Biggi, Alberto
    Hauns, Bernhard
    Mais, Anna
    Henning, Stefan W.
    Hentsch, Bernd
    [J]. BLOOD, 2010, 116 (21) : 1159 - 1159
  • [2] Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study
    Walewski, Jan
    Paszkiewicz-Kozik, Ewa
    Borsaru, Gabriela
    Hellmann, Andrzej
    Janikova, Andrea
    Warszewska, Agnieszka
    Mais, Anna
    Ammendola, Astrid
    Herz, Thomas
    Krauss, Babett
    Henning, Stefan W.
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (03) : 675 - 684
  • [3] A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Fanale, M.
    Pro, B.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Dubay, M.
    Backstrom, J.
    Martell, R. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma
    Walewski, Jan
    Paszkiewicz-Kozik, Ewa
    Warszewska, Agnieszka
    Borsaru, Gabriela
    Moicean, Andreea
    Hellmann, Andrzej
    Mayer, Jiri
    Hauns, Bernhard
    Mais, Anna
    Henning, Stefan W.
    Hentsch, Bernd
    [J]. BLOOD, 2011, 118 (21) : 1149 - 1149
  • [5] A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
    Christian, Beth
    Wei, Lai
    Sexton, Jennifer
    Jaglowski, Samantha M.
    Devine, Steven M.
    Fehniger, Todd A.
    Wagner-Johnston, Nina
    Bartlett, Nancy L.
    Blum, Kristie A.
    [J]. BLOOD, 2014, 124 (21)
  • [6] A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
    Christian, Beth
    Kopko, Anne
    Fehniger, Todd A.
    Bartlett, Nancy L.
    Blum, Kristie A.
    [J]. BLOOD, 2012, 120 (21)
  • [7] Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients
    Viviani, S.
    Bonfante, V.
    Fasola, C.
    Valagussa, P.
    Gianni, A. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] A phase II study of MGCD0103, a novel oral isotype-selective histone deacetylase inhibitor, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Pro, B.
    Fanale, M.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Li, Z.
    Ward, R.
    Martell, R. E.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 28 - 29
  • [9] A phase II multicenter study of abexinostat, an oral histone deacetylase inhibitor, in patients with relapsed/refractory follicular lymphoma
    Shi, Yuankai
    Gui, Lin
    Cheng, Ying
    Wang, Huaqing
    Cao, Junning
    Li, Yufu
    Yu, Yong
    Gao, Yuhuan
    Li, Zhenling
    Shen, Jianzhen
    Zhang, Lei
    Zhang, Qingyuan
    Pan, Qin
    Wang, Zhen
    Ke, Xiaoyan
    He, Hesheng
    Guo, Shuangshuang
    Wang, Yihao
    Xu, Xiaohong
    Zou, Liqun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] EFFICIENT HDAC INHIBITION AND TARC REDUCTION IN PATIENTS WITH REFRACTORY HODGKIN LYMPHOMA TREATED WITH RESMINOSTAT - PK/PD DATA FROM THE PHASE II SAPHIRE STUDY
    Walewski, J.
    Henning, W.
    Borsaru, G.
    Moicean, A.
    Hellmann, A.
    Janikova, A.
    Hauns, B.
    Mais, A.
    Ammendola, A.
    Herz, T.
    Kohlhof, H.
    Hentsch, B.
    [J]. HAEMATOLOGICA, 2012, 97 : 83 - 83
12345